EUROPEAN SYMPOSIUM

IV Wildbad Kreuth Initiative - Optimal use of clotting factors and platelets
6-7 May 2016, Freising, Germany
Duration: 2.5 days. Working language: English

***

DRAFT PROGRAMME

THURSDAY 5 MAY 2016
16:00-18:00
- Registration for participants
- Pre-meeting for speakers
19:00-21:30
- Buffet Dinner

FRIDAY 6 MAY 2016
8:00 Welcome
Prof Dr Karl-Walter Jauch, Medical Director, University Munich
Dr Michael Wierer, EDQM, Council of Europe

SESSION 1 (Plenary): Clinical use of clotting factors and platelets - Challenges
Moderators & Rapporteurs: Pier Mannucci, Rainer Seitz, Michael Wierer

8:30-8:50 Optimal use of blood components – rationale for Wildbad-Kreuth Initiative IV
Wolfgang Schramm, University of Munich, DE

8:50-9:10 Continuing the Kreuth Initiative: Current controversies in clinical use of blood components
Rainer Seitz, Paul Ehrlich Institut, Langen, DE

9:10-9:30 Quality indicators for monitoring the Clinical Use of Blood
Constantina Politis, Coordinating Haemovigilance Centre, Athens, GR

9:30-9:50 How novel drugs change treatment in haemophilia
Flora Peyvandi, University of Milan, IT

9:50-10:10 Current challenges using platelet concentrates
Jean-Pierre Cazenave, ARMESA, Strasbourg, FR

10:10-10:40 Bavarian break

10:40-11:00 Regulatory and health technology assessment requirements
Jan Müller-Berghaus, Paul Ehrlich Institut, Langen, DE

11:00-11:20 Current challenges of benefit/effectiveness/risk assessment (haemophilia and platelets)
Karin Berger, University Hospital of Munich, DE

11:20-11:40 Patients organisations’ view
Brian O’Mahony, European Haemophilia Consortium (EHC), Dublin, IE

11:40-13:00 Lunch break
WORKSHOPS (parallel sessions)
SESSION 2: Clotting Factors: Impulse Presentations (parallel session)
Moderators & Rapporteurs: Paul Giangrande, Pier Mannucci, Brian O’Mahony, Flora Peyvandi

13:00-13:20 Clinical trials of clotting factors/regulatory aspects
Anneliese Hilger, Paul Ehrlich Institut, Langen, DE

13:20-13:40 Inhibitor development in PUPs – a comparison of previous studies and the Sippet study
Frits Rosendaal, Leids Universitair Medisch Centrum, NL

13:40-14:00 Inhibitors: Prophylaxis and Immune Tolerance Induction (ITI)
Hervé Chambost, University Hospital of Marseille, FR

14:00-14:20 Access: supply, procurement, tenders
Paul Giangrande, University of Oxford, UK

14:20-14:40 Haemophilia care in Europe and USA – 2014/15 data and future trends
Patrick Robert, the Marketing Research Bureau Inc, Orange, USA

SESSION 3: Platelets: Impulse Presentations (parallel session)
Moderators & Rapporteurs: Karin Berger, Jean-Pierre Cazenave, Sheila McLennan, Dorothea Stahl

13:00-13:20 Current practice in platelet transfusion
Gregor Bein, University Hospital of Giessen & Marburg, DE

13:20-13:40 How do we assess clinical efficacy of platelet transfusion?
Miguel Lozano, Hospital Clinic of Barcelona, ES

13:40-14:00 Infectious risk: Testing strategies, pathogen inactivation
Sheila McLennan, National Health Service, Leeds, UK

14:00-14:20 Immunogenicity: Process related issues (buffy coat vs apheresis platelets)
Olivier Garraud, National Institute of Blood Transfusion (INTS), Paris, FR

14:20-14:40 Availability of platelet concentrates in Europe
Dorothea Stahl, Paul Ehrlich Institut, Langen, DE

14:40-15:00 Coffee break

15:00-17:00 Working Groups

Working Group 1: Clotting factor concentrates
Moderators & Rapporteurs: Paul Giangrande, Flora Peyvandi, Brian O’Mahony

Working Group 2: Platelet-concentrates
Moderators & Rapporteurs: Jean-Pierre Cazenave, Sheila McLennan, Dorothea Stahl, Karin Berger

17:00-17:30 Preparation of interim reports
SESSION 4 (Plenary): Summary of discussions – Interim reports of the Working Groups sessions

17:30-18:00 Presentation and synthesis of workshops
18:00 Close of meeting
20:00 Evening Dinner

SATURDAY 7 MAY 2016 – (Only open to public sector organisations representatives)

8:00-10:00 Discussion in the Working Groups (parallel sessions), preparation of final reports
10:00-10:30 Coffee break
10:30-12:30 Final reports from the Working Groups
   Moderators: Rainer Seitz & Michael Wierer
   • Working Group 1: Clotting factors
   • Working Group 2: Platelets
12:30-13:30 Lunch break
13:30-16:00 Conclusions and Recommendations

SCIENTIFIC PROGRAMME COMMITTEE

Prof Dr Rainer SEITZ  Dr Karin BERGER
Dr Marie-Emmanuelle BEHR-GROSS  Dr Anneliese HILGER
Dr Karl-Heinz BUCHHEIT  PD Dr Dorothea STAHL
Prof Dr Wolfgang SCHRAMM  Dr Michael WIERER

Meeting Venue: see http://www.bildungszentrum-freising.de/